Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
1 finding from 1 review
Improvement in disability grade Defined as achievement of a specified degree of improvement · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes improvement in disability grade Defined as achievement of a… compared with placebo (very low certainty).
1 finding from 1 review
Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome
1 finding from 1 review
Time from randomisation until discontinuation of ventilation (for those ventilated) · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients with Guillain‐Barré syndrome
Interferon beta‐1a showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Change in disability after 26 or more weeks · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants who completed the study and did not restart IVIg therapy after IVIg withdrawal · people with CIDP
Interferon beta‐1a showed no clear difference in participants who completed the study and did not restart IVIg… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review